Share CCO Oncology Podcast
Share to email
Share to Facebook
Share to X
By Clinical Care Options
4.9
88 ratings
The podcast currently has 185 episodes available.
In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including:
Presenter:
Caitlin Costello, MD
Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego
La Jolla, California
Link to full program:
https://bit.ly/40bjFCZ
In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including:
Presenters:
Thor R. Halfdanarson, MD
Consultant, Division of Medical Oncology
Professor of Oncology
Associate Professor of Medicine
Mayo Clinic Comprehensive Cancer Center
Chair, Hepato-Pancreatico-Biliary Disease Group
Rochester, Minnesota
Jonathan Strosberg
Professor, GI Oncology
Chair, Neuroendocrine Tumor Division
Moffitt Cancer Center and Research Institute
Tampa, Florida
Link to full program:
https://bit.ly/3Y0JWBa
In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including:
Program faculty:
Ana Oaknin, MD, PhD
Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology
Barcelona, Spain
Alexandra Leary, MD, PhD
Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab,
Institut Gustave Roussy
Paris, France
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:
Program faculty:
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Lindsey Roeker, MD
Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Resources:
To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page.
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:
Program faculty:
Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:
Program faculty:
Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:
Program faculty:
Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Resources:
To download the slides associated with this podcast discussion, please visit the program page
In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including:
Program faculty:
Floor J. Backes, MD
Professor
Director of Clinical Research
Division of Gynecologic Oncology
Associate Fellowship Director
Department of Obstetrics and Gynecology
The Ohio State University College of Medicine
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio
Angeles Alvarez Secord, MD, MHSc
Professor of Obstetrics & Gynecology
Division of Gynecologic Oncology
Director, Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer.
Presenters:
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California
Sarah Sammons, MD
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Link to full program:
https://bit.ly/46hLGcM
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:
Presenters:
Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas
Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.
Link to full program:
https://bit.ly/3LzA2As
The podcast currently has 185 episodes available.
73 Listeners
30,751 Listeners
298 Listeners
38 Listeners
12 Listeners
457 Listeners
25,877 Listeners
57 Listeners
3,285 Listeners
44 Listeners
22 Listeners
53 Listeners
362 Listeners
1,406 Listeners
153 Listeners